I
1.55
-0.04 (-2.52%)
| Previous Close | 1.59 |
| Open | 1.57 |
| Volume | 1,215,345 |
| Avg. Volume (3M) | 1,867,365 |
| Market Cap | 95,538,984 |
| Price / Sales | 3.32 |
| Price / Book | 5.98 |
| 52 Weeks Range | |
| Earnings Date | 10 Dec 2025 |
| Profit Margin | -194.79% |
| Operating Margin (TTM) | -53.47% |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | -1.10% |
| Total Debt/Equity (MRQ) | 51.46% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -7.91 M |
| Levered Free Cash Flow (TTM) | -3.63 M |
| Return on Assets (TTM) | -14.88% |
| Return on Equity (TTM) | -124.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ImmunoPrecise Antibodies Ltd. | Bearish | Bearish |
AIStockmoo Score
-1.1
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.13 |
|
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.21% |
| % Held by Institutions | 8.65% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |